Disease-modifying anti rheumatic drugs (DMARDs) is a category of otherwise unrelated drugs defined by their use in rheumatoid arthritis to slow down disease progression. The term is often used in contrast to no steroidal anti-inflammatory drug  and steroids  The term "ant rheumatic" can be used in similar contexts, but without making a claim about an effect on the course. Other terms that have historically been used to refer to the same group of drugs are "remission-inducing drugs" and "slow-acting anti-rheumatic drugs”. Although the use of the term DMARDs was first propagated in rheumatoid arthritis (hence their name) the term has come to pertain to many other diseases, such as Crohn's disease, lupus erythematosus (SLE), Sjögren syndrome, immune thrombocytopenic purpura (ITP), myasthenia gravis, sarcoidosis and various others.The term was originally introduced to indicate a drug that reduce evidence of processes thought to underlie the disease, such as a raised erythrocyte sedimentation rate, reduced haemoglobin level, raised rheumatoid factor level and more recently, a raised C-reactive protein level.[citation needed] More recently, the term has been used to indicate a drug that reduces the rate of damage to bone and cartilage. DMARDs can be further subdivided into traditional small molecular mass drugs synthesised chemically and newer "biological" agents produced through genetic engineering Some DMARDs  are mild chemotherapeutics but use a side-effect of chemotherapy—immunosuppression—as its main therapeutically benefit. Anti rheumatic drugs peer-review journals has been successfully publishing quality Research articles from many years and looking forward to frame up eminent, outstanding issues with best quality research articles in this year. We request you to kindly submit and publish your paper in this best journal and get global acknowledgment